AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Americana Partners LLC

Americana Partners LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,413 shares of the company’s stock after acquiring an additional 395 shares during the period. Americana Partners LLC’s holdings in AstraZeneca were worth $2,214,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in shares of AstraZeneca by 17.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after purchasing an additional 9,002,450 shares in the last quarter. Swedbank AB bought a new position in shares of AstraZeneca in the first quarter worth $186,127,000. Manning & Napier Advisors LLC bought a new position in shares of AstraZeneca in the second quarter worth $188,476,000. Hsbc Holdings PLC grew its stake in shares of AstraZeneca by 750.3% in the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after purchasing an additional 1,132,362 shares in the last quarter. Finally, Farallon Capital Management LLC grew its stake in shares of AstraZeneca by 65.1% in the second quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after purchasing an additional 950,000 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Trading Up 0.4 %

Shares of NASDAQ AZN opened at $71.42 on Friday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a market cap of $221.44 billion, a price-to-earnings ratio of 34.50, a P/E/G ratio of 1.32 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $79.17 and a 200-day simple moving average of $78.60.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.